Chief Executive, Managing Director, Joint Chief Technical Officer & Interim Head of Business Development since 2021 / Arovella Therapeutics
Dr Michael Baker joined SUDA Pharmaceuticals as chief executive in January 2020.
Dr Baker is the investment manager of Australian life science fund, Bioscience Managers, and was responsible for deal sourcing from networks, conferences, universities and research institutes. He also conducted the due diligence to shortlist investment opportunities and managed portfolios, specifically helping investee companies with corporate and operational strategies and fund raisings. Prior to that, Dr Baker was a project manager at Hexima which specialises in developing agricultural and pharmaceutical products.
Dr Baker has a PhD in Biochemistry and was awarded the prestigious Nancy Millis award for the most outstanding thesis for the Faculty of Science, Tech and Engineering in 2010.
He was an Alexander von Humboldt Research Fellow at the University of Cologne with nine publications, one in the prestigious journal Science. He was also awarded an MBA at Melbourne Business School – Dean’s List.